Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Prostaglandin I(2) (epoprostenol) triggers migraine-like attacks in migraineurs

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Monitoring chronic headache and medication-overuse headache prevalence in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. PACAP27 induces migraine-like attacks in migraine patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Neck pain and headache after whiplash injury: a systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Von Frey testing revisited - provision of an online algorithm for improved accuracy of 50% thresholds

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Wienecke T, Olesen J & Ashina M. Prostaglandin I(2) (Epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 2009. London. ISSN 0333-1024Prostacyclin [prostaglandin I(2) (PGI(2))] activates and sensitizes meningeal sensory afferents. In healthy subjects PGI(2) triggers headache in healthy subjects. However, the migraine-eliciting effect of PGI(2) has not been systematically studied in patients with migraine. We hypothesized that intravenous infusion of the stable prostacyclin analogue epoprostenol would trigger migraine-like attacks in migraineurs. We infused 10 ng kg(-1) min(-1) PGI(2) or placebo over 25 min in 12 migraineurs without aura in a controlled, double-blind, cross-over study and recorded headache intensity and associated symptons, velocity in the middle cerebral artery (V(MCA)) and diameter in the superficial temporal artery. In the period 0-14 h, 12 subjects reported headache on PGI(2) day compared with three subjects on placebo day (P = 0.004), and six subjects fulfilled the criteria for an experimentally induced migraine-like attack compared with two subjects on placebo (P = 0.219). During infusion and post-infusion phases the AUC under the headache curve on PGI(2) was significantly larger than on placebo (P < 0.05). There was a significant V(MCA) decrease (P = 0.015) and superficial temporal artery diameter increase (P < 0.001) on PGI(2) compared with placebo. In conclusion, PGI(2) may trigger a migraine-like attack in migraine sufferers. We suggest sensitization of perivascular nociceptors and arterial dilation as the mode of action of PGI(2)-induced headache and migraine-like attacks.
OriginalsprogEngelsk
TidsskriftCephalalgia : an international journal of headache
Vol/bind30
Udgave nummer2
Sider (fra-til)179-190
Antal sider11
DOI
StatusUdgivet - 2010

ID: 172137